ModernMedicine Resource Center More Topics


Testosterone Therapy and Cardiovascular Risk

Dr. Abraham Morgentaler, an Associate Clinical Professor of Urology at Harvard Medical School, explores and clarify in the February 2015 issue of Mayo Clinic Proceedings, the value of testosterone therapy in men, and in particular the issue of cardiovascular risk.

The Lowdown on Low T

High, low testosterone levels linked to higher mortality risk
High, low testosterone levels linked to higher mortality riskOlder men with midrange testosterone levels tend to live longer compared with men who have low or high levels, Australian researchers say.
Compounding pharmacies recall low T medicationsTwo California compounding pharmacies have announced voluntary recalls of testosterone products.
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPH
Testosterone doesn’t worsen lower urinary tract symptoms in men with BPHA new study has found that testosterone replacement doesn’t worsen lower urinary tract symptoms related to an enlarged prostate. In fact, many men saw their symptoms improve, apparently with little effect on their prostate gland.
Study confirms low testosterone in crizotinib patientsA new multinational study confirms the impact of the recently-approved lung cancer medication, crizotinib, on testosterone. The study was published online first in the April 12, 2013, issue of Cancer.
Testosterone replacement therapy displays long-term safety, efficacy in post-radical prostatectomy menResults of a single-institution study support the long-term safety and efficacy of testosterone replacement therapy for treating hypogonadism in men who have undergone radical prostatectomy.
Testosterone 'best indicator' of men's health, according to expertsTestosterone, a hormone somewhat relegated to background status for many years, is moving to the fore as a central factor in men's health and disease.
Survey: Urologist views on active surveillance for prostate cancer complexHaving a positive attitude regarding active surveillance for patients with low-risk prostate cancer does not correlate with the likelihood that radiation oncologists and urologists will recommend it in lieu of treatment.
Testosterone replacement therapy viable in patients with localized prostate cancerTestosterone replacement therapy (TRT) did not increase the risk of biochemical recurrence in hypogonadal men with localized prostate cancer.
TRT linked with weight loss, improvement of metabolic syndrome symptomsTestosterone replacement therapy may result in weight reduction and improvement in symptoms of metabolic syndrome, according to separate studies presented at the Endocrine Society annual meeting in Houston.